Proton beam therapy for unresectable intrahepatic cholangiocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 5, 2015, Pages 957-963

  Ohkawa, Ayako ^a   Mizumoto, Masashi ^a   Ishikawa, Hitoshi ^a   Abei, Masato ^a   Fukuda, Kuniaki ^a   Hashimoto, Takayuki ^a   Sakae, Takeji ^a   Tsuboi, Koji ^a   Okumura, Toshiyuki ^a   Sakurai, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Intrahepatic cholangiocarcinoma; Proton beam therapy; Radiotherapy; Unresectable

Indexed keywords

GEMCITABINE; GIMERACIL; OTERACIL; TEGAFUR; ANTINEOPLASTIC AGENT; DRUG COMBINATION; S 1 (COMBINATION);

ADULT; AGED; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT INFECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DERMATITIS; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; INOPERABLE CANCER; MALE; NAUSEA; PHOTON THERAPY; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; STOMACH ULCER; SURVIVAL RATE; TREATMENT OUTCOME; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DRUG COMBINATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROTON THERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926638364     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12843     Document Type: Article

References (34)

1. Ikai I, Arii S, Okazaki M etal. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol. Res. 2007; 37: 676-691.
2. Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr. Opin. Gastroenterol. 2013; 29: 324-328.
3. Park J, Kim MH, Kim KP etal. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009; 3: 298-305.
4. Fukumitsu N, Sugahara S, Nakayama H etal. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 831-836.
5. Mizumoto M, Tokuuye K, Sugahara S etal. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 462-467.
6. Nakayama H, Sugahara S, Fukuda K etal. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int. J. Radiat. Oncol. Biol. Phys. 2011; 80: 992-995.
7. Mizumoto M, Okumura T, Hashimoto T etal. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 1039-1045.
8. Nakayama H, Sugahara S, Tokita M etal. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009; 115: 5499-5506.
9. Sugahara S, Oshiro Y, Nakayama H etal. Proton beam therapy for large hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76: 460-466.
10. Sugahara S, Nakayama H, Fukuda K etal. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther. Onkol. 2009; 185: 782-788.
11. Hata M, Tokuuye K, Kagei K etal. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 786-793.
12. Hata M, Tokuuye K, Sugahara S etal. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006; 107: 591-598.
13. Hata M, Tokuuye K, Sugahara S etal. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005; 104: 794-801.
14. Hata M, Tokuuye K, Sugahara S etal. Proton beam therapy for aged patients with hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 805-812.
15. Mizumoto M, Tokuuye K, Sugahara S etal. Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: report of three cases. Jpn J. Clin. Oncol. 2007; 37: 459-462.
16. Tsunashima Y, Sakae T, Shioyama Y etal. Correlation between the respiratory waveform measured using a respiratory sensor and 3D tumor motion in gated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60: 951-958.
17. Oshiro Y, Okumura T, Ishida M etal. Displacement of hepatic tumor at time to exposure in end-expiratory-triggered-pulse proton therapy. Radiother. Oncol. 2011; 99: 124-130.
18. Paganetti H, Niemierko A, Ancukiewicz M etal. Relative biological effectiveness (RBE) values for proton beam therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53: 407-421.
19. Common Terminology Criteria for Adverse Events (CTCAE) V.4.0. 2013. Bethesda, MD, USA: National Institute of Health, National Cancer Institute, 2009.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 31: 457-481.
21. Sulpice L, Rayar M, Boucher E etal. Treatment of recurrent intrahepatic cholangiocarcinoma. Br. J. Surg. 2013; 99: 1711-1717.
22. Wang Y, Li J, Xia Y etal. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J. Clin. Oncol. 2013; 31: 1188-1195.
23. Ebata T, Kamiya J, Nishio H etal. The concept of perihilar cholangiocarcinoma is valid. Br. J. Surg. 2009; 96: 926-934.
24. Ohtsuka M, Ito H, Kimura F etal. Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 2003; 10: 259-264.
25. Valle J, Wasan H, Palmer DH etal. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010; 362: 1273-1281.
26. Andre T, Reyes-Vidal JM, Fartoux L etal. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br. J. Cancer 2008; 99: 862-867.
27. Riechelmann RP, Townsley CA, Chin SN etal. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110: 1307-1312.
28. Sasaki T, Isayama H, Nakai Y etal. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother. Pharmacol. 2010; 65: 1101-1107.
29. Kim YJ, Im SA, Kim HG etal. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann. Oncol. 2008; 19: 99-103.
30. Ray CE Jr, Edwards A, Smith MT etal. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J. Vasc. Interv. Radiol. 2013; 24: 1218-1226.
31. Shinohara ET, Mitra N, Guo M etal. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 1495-1501.
32. Fu Y, Yang W, Wu W etal. Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma. Chin. J. Cancer Res. 2011; 23: 295-300.
33. Kopek N, Holt MI, Hansen AT etal. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother. Oncol. 2010; 94: 47-52.
34. Polistina FA, Guglielmi R, Baiocchi C etal. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother. Oncol. 2011; 99: 120-123.